OptimizeRx (OPRX) Competitors $8.28 -0.10 (-1.13%) As of 11:13 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPRX vs. ACCD, WLDN, PRTH, THRY, MAX, MEG, DDI, RMR, NVRI, and RPAYShould you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Accolade (ACCD), Willdan Group (WLDN), Priority Technology (PRTH), Thryv (THRY), MediaAlpha (MAX), Montrose Environmental Group (MEG), DoubleDown Interactive (DDI), The RMR Group (RMR), Enviri (NVRI), and Repay (RPAY). These companies are all part of the "business services" industry. OptimizeRx vs. Accolade Willdan Group Priority Technology Thryv MediaAlpha Montrose Environmental Group DoubleDown Interactive The RMR Group Enviri Repay OptimizeRx (NASDAQ:OPRX) and Accolade (NASDAQ:ACCD) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Which has more risk & volatility, OPRX or ACCD? OptimizeRx has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Accolade has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Does the MarketBeat Community favor OPRX or ACCD? OptimizeRx received 55 more outperform votes than Accolade when rated by MarketBeat users. Likewise, 64.08% of users gave OptimizeRx an outperform vote while only 55.14% of users gave Accolade an outperform vote. CompanyUnderperformOutperformOptimizeRxOutperform Votes15764.08% Underperform Votes8835.92% AccoladeOutperform Votes10255.14% Underperform Votes8344.86% Which has higher valuation and earnings, OPRX or ACCD? OptimizeRx has higher earnings, but lower revenue than Accolade. OptimizeRx is trading at a lower price-to-earnings ratio than Accolade, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOptimizeRx$92.13M1.68-$17.57M-$1.10-7.62Accolade$446.72M1.29-$99.81M-$2.25-3.12 Do analysts prefer OPRX or ACCD? OptimizeRx presently has a consensus target price of $9.06, indicating a potential upside of 8.14%. Accolade has a consensus target price of $6.51, indicating a potential downside of 7.31%. Given OptimizeRx's stronger consensus rating and higher probable upside, research analysts clearly believe OptimizeRx is more favorable than Accolade.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OptimizeRx 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78Accolade 0 Sell rating(s) 13 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.07 Does the media favor OPRX or ACCD? In the previous week, OptimizeRx had 3 more articles in the media than Accolade. MarketBeat recorded 4 mentions for OptimizeRx and 1 mentions for Accolade. OptimizeRx's average media sentiment score of 0.35 beat Accolade's score of 0.00 indicating that OptimizeRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OptimizeRx 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Accolade 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OPRX or ACCD more profitable? OptimizeRx has a net margin of -27.41% compared to Accolade's net margin of -40.36%. OptimizeRx's return on equity of -4.92% beat Accolade's return on equity.Company Net Margins Return on Equity Return on Assets OptimizeRx-27.41% -4.92% -3.41% Accolade -40.36%-20.74%-11.33% Do institutionals & insiders hold more shares of OPRX or ACCD? 76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 85.0% of Accolade shares are owned by institutional investors. 6.1% of OptimizeRx shares are owned by insiders. Comparatively, 8.2% of Accolade shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryOptimizeRx beats Accolade on 14 of the 19 factors compared between the two stocks. Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPRX vs. The Competition Export to ExcelMetricOptimizeRxBusiness services IndustryComputer SectorNASDAQ ExchangeMarket Cap$154.95M$20.31B$22.62B$7.70BDividend YieldN/A2.74%3.01%4.32%P/E Ratio-6.3033.8841.4418.33Price / Sales1.686.992,183.69107.05Price / CashN/A32.3034.6934.62Price / Book1.205.406.024.25Net Income-$17.57M$681.59M$735.88M$247.51M7 Day Performance-0.83%15.20%4.17%6.33%1 Month Performance-11.51%4.41%-3.76%-3.33%1 Year Performance-4.77%30.57%52,586.12%5.15% OptimizeRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPRXOptimizeRx1.2427 of 5 stars$8.29-1.1%$9.06+9.4%-8.5%$153.26M$92.13M-6.23100ACCDAccolade2.1916 of 5 stars$7.02flat$6.51-7.3%N/A$575.59M$446.72M-3.122,350Positive NewsWLDNWilldan Group4.6199 of 5 stars$36.90-4.1%$51.50+39.6%+36.7%$531.66M$565.80M22.641,560Positive NewsPRTHPriority Technology3.7025 of 5 stars$6.60-5.0%$13.67+107.1%+133.3%$524.83M$879.70M-15.71790THRYThryv2.1087 of 5 stars$11.77-2.5%$22.50+91.2%-43.5%$510.48M$824.16M-1.222,960Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsMAXMediaAlpha3.5115 of 5 stars$7.49-3.6%$18.07+141.3%-55.6%$502.06M$864.70M44.06160Upcoming EarningsAnalyst ForecastNews CoverageMEGMontrose Environmental Group2.9348 of 5 stars$13.97-4.2%$31.40+124.8%-63.4%$484.26M$696.40M-9.382,500Positive NewsDDIDoubleDown Interactive3.825 of 5 stars$9.77-0.8%$20.67+111.5%-8.7%$484.13M$341.33M3.89220News CoveragePositive NewsGap DownRMRThe RMR Group2.7627 of 5 stars$14.96-1.4%$32.00+113.9%-35.7%$476.42M$855.39M11.25600Ex-DividendAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsNVRIEnviri1.8733 of 5 stars$5.85-0.2%$10.00+70.9%-16.5%$469.25M$2.34B-3.6812,000Upcoming EarningsNews CoveragePositive NewsRPAYRepay3.3757 of 5 stars$4.36-0.9%$9.94+127.9%-55.8%$425.05M$313.04M-5.01580News CoveragePositive News Related Companies and Tools Related Companies Accolade Alternatives Willdan Group Alternatives Priority Technology Alternatives Thryv Alternatives MediaAlpha Alternatives Montrose Environmental Group Alternatives DoubleDown Interactive Alternatives The RMR Group Alternatives Enviri Alternatives Repay Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPRX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
